Oncolytics Biotech Inc. (ONCY) vs RenovoRx, Inc. (RNXT)

A side-by-side comparison of Oncolytics Biotech Inc. and RenovoRx, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ONCY vs RNXT

growth of $100 · dividends reinvested · last 5y
ONCY -73.2% (-23.2%/yr)RNXT -79.8% (-27.3%/yr)ONCY compounded faster over this window
050100150200Start $10020222023202420252026$27$20
ONCY RNXT

ONCY vs RNXT: by the numbers

  • •RNXT is the larger company ($63M vs $60M market cap).
  • •Both run net losses; ONCY's is the smaller (0.00% vs -621.71% net margin).

Metrics side by side

Valuation

MetricONCYRNXT
P/S ratioN/A31.69
P/B ratioN/A6.97

Profitability

MetricONCYRNXT
Gross margin0.00%70.88%
Operating margin0.00%-1113.98%
Net margin0.00%-621.71%
ROEN/A-136.82%
ROIC-1235.48%-139.74%

Growth (annualized)

MetricONCYRNXT
Total return CAGR (5Y)-21.00%-23.80%

Frequently asked

How have ONCY and RNXT total returns compared?
Over the past 5 years, ONCY delivered -21.00% and RNXT delivered -23.80% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.